Dextroamphetamine monosaccharate | 300666-47-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Dextroamphetamine monosaccharate
• 英文别名: (2S)-1-phenylpropan-2-amine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanedioic acid
• CAS: 300666-47-1；799787-69-2
• 化学式: C15H23NO8
• 分子量: 345.34
• InChiKey: VHKVKWTWHZUFIA-DGOKBZBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.82
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  182
• 氢给体数：
  7
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (S)-diethyl (1-phenylpropan-2-yl)phosphoramidate 在 盐酸 、 硫酸 、 sodium hydroxide 作用下， 以 水 、 异丙醇 为溶剂， 反应 9.5h， 生成 Dextroamphetamine monosaccharate
  参考文献：
  名称：

  Non-distillative Process for Manufacturing High Purity Amphetamines

  摘要：

  The invention provides a non-distillative process for manufacturing amphetamine and substituted amphetamines, comprising obtaining a highly pure phosphoramidate compound, converting the highly pure phosphoramidate compound to an amphetamine sulfate compound, concentrating the amphetamine sulfate compound in isopropanol, and then salting out the amphetamine compound directly to obtain an amphetamine salt, the amphetamine salt selected from amphetamine saccharate, amphetamine sulfate, amphetamine aspartate, alkyl-amphetamine saccharate, alkyl-amphetamine sulfate, alkyl-amphetamine aspartate, aryl-amphetamine saccharate, aryl-amphetamine sulfate, aryl-amphetamine aspartate, and mixtures thereof.

  公开号：

  US20240286993A1

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• [EN] FAAH INHIBITORS<br/>[FR] INHIBITEURS DE FAAH
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2012088469A1

  公开（公告）日：2012-06-28

  The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.

  本公开涉及作为脂肪酰胺水解酶（FAAH）抑制剂有用的化合物。该公开还提供包括本公开化合物的药学上可接受的组合物，以及使用这些组合物在治疗或预防各种疾病中的方法。发明的化合物在表1中描述。
• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Claffey Michelle M.

  公开号：US20100190771A1

  公开（公告）日：2010-07-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  这项发明提供了式（I）中的PDE9抑制化合物，以及其药学上可接受的盐，其中R1、R2、R3、A和n的定义如本文所述。还提供了含有式I中化合物的药物组合物，并且提供了在治疗神经退行性和认知障碍疾病，如阿尔茨海默病和精神分裂症中的用途。
• Novel Cyclopropabenzofuranyl Pyridopyrazinediones
  申请人：Pfizer Inc.

  公开号：US20160222007A1

  公开（公告）日：2016-08-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 10 , R 11 , and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  揭示了化合物及其在药学上可接受的盐，其中该化合物具有Formula I的结构 其中X，R 1 ，R 2a ，R 2b ，R 4a ，R 4b ，R 5a ，R 5b ，R 6 ，R 7 ，R 10 ，R 11 和y如规范中所定义。还公开了相应的药物组合物、治疗方法、合成方法和中间体。
• [EN] CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS<br/>[FR] CHROMÈNE ET 1,1A,2,7B-TÉTRAHYDROCYCLOPROPA[C]CHROMÈNE PYRIDOPYRAZINEDIONES COMME MODULATEURS DE GAMMA-SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2015150957A1

  公开（公告）日：2015-10-08

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. These compounds are γ-secretase modulators, useful for the treatment of neurodegenerative and/ or neurological disorders such as Alzheimer's disease and Down's syndrome.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有式（I）的结构，其中X、R1、R2a、R2b、R4a、R4b、R5a、R5b、R6、R7、y和z如规范中所定义。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。这些化合物是γ-分泌酶调节剂，可用于治疗神经退行性和/或神经系统疾病，如阿尔茨海默病和唐氏综合征。